ticarcillin

Trade name: ticar

Small moleculeapproved

Approved

Nov 9, 1976

Ticarcillin (also known as Ticar) is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. Ticarcillin is not absorbed orally; therefore, it must be given intravenously or intramuscularly. Ticarcillin's antibiotic properties arise from its ability to prevent cross-linking of peptidoglycan during cell wall synthesis when the bacteria tries to divide, causing death. Usage of ticar was discontinued. — NCATS

Clinical trial activity

8 trials · 14 clinical orgs · 1 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Mar 1, 2002 (NCT00092170)

Timeline

1970s

Nov 9, 1976
GlaxoSmithKline — Earliest FDA Approval
Nov 9, 1976
GlaxoSmithKline — NDA Secondary Org
Nov 9, 1976
GlaxoSmithKline — NDA Organization

1980s

Dec 19, 1986
GlaxoSmithKline — Marketing Organization

2000s

Jan 1, 2002
Earliest Phase 2 Sponsor(trial)

2010s

Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Jan 1, 2013
Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor

Combination products

timentin
with clavulanate

Approval history

approvedNov 9, 1976

Chemistry & pharmacology

Loading structure…

SMILES

CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)C3=CSC=C3)C(=O)N2[C@H]1C(O)=O

Mol. weight: 384.427 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Parenteral
Availability: Discontinued

Oral

Parenteral

Yes

Topical

Sources

Also known as

(2s,5r,6r)-6-{[(2r)-2-carboxy-2-thiophen-3-ylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2s,5r,6r)-6-{[(2r)-2-carboxy-2-thiophen-3-ylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
alpha-carboxy-3-thienylmethylpenicillin
alpha-carboxy-3-thienylmethylpenicillin
brl-2288
brl-2288
brl 28500
brl-28500
ticar
ticar
ticar
ticaracillin
ticarcilina
ticarcilina
ticarcillin
ticarcillin
ticarcillin
ticarcillin
ticarcillin
ticarcillin
ticarcillin
ticarcillin
ticarcillin
ticarcillin
ticarcillin-clavulanic acid
ticarcillin-clavulanic acid
ticarcillin disodium
ticarcillin disodium
ticarcillin disodium
ticarcillin disodium
ticarcilline
ticarcilline
ticarcillin monosodium
ticarcillin monosodium
ticarcillin sodium
ticarcillin sodium
ticarcillin sodium
ticarcillin supplement
ticarcillin supplement
ticarcillinum
ticarcillinum
timentin
timentin
timentin

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT02800785	N/A	May 1, 2016	Cancer Research Network, University of California, Los Angeles, University of Washington
NCT02099240	Early Phase 1 (Phase 1)	Apr 1, 2014	James Graham Brown Cancer Center, University of Louisville
NCT02158442	Phase 2	Oct 1, 2013	Osprey Medical, Inc, University of Melbourne
NCT01931150	Phase 3	Aug 1, 2013	Bristol-Myers Squibb, Cornell University
NCT01667094	Phase 4	Sep 1, 2012	Monash University, The Alfred Hospital
NCT01229046	Phase 1	Sep 1, 2010	Duke University
NCT00153634	N/A	Mar 1, 2004	Cystic Fibrosis Foundation Therapeutics, University of Washington
NCT00092170	Phase 2	Mar 1, 2002	Merck

Showing 8 of 8 trials

Page 1 / 1

Organizations

Research & Development (14)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
University of Washington	Academic/Hospital	2	2	1	2004
Bristol-Myers Squibb	For profit	1	0	1	2013
Cancer Research Network	Academic/Hospital	1	0	1	2016
Cornell University	Academic/Hospital	1	1	1	2013
Cystic Fibrosis Foundation Therapeutics	Academic/Hospital	1	0	1	2004
Duke University	Academic/Hospital	1	1	1	2010
James Graham Brown Cancer Center	Academic/Hospital	1	0	1	2014
Merck	For profit	1	1	1	2002
Monash University	Academic/Hospital	1	1	1	2012
Osprey Medical, Inc	For profit	1	1	1	2013
The Alfred Hospital	Academic/Hospital	1	0	1	2012
University of California, Los Angeles	Academic/Hospital	1	0	1	2016
University of Louisville	Academic/Hospital	1	1	1	2014
University of Melbourne	Academic/Hospital	1	0	1	2013

14 organizations

Page 1 / 1

Marketing (3)

Organization	Org type	Relationship	Date
GlaxoSmithKline	For profit	NDA2	Nov 9, 1976
GlaxoSmithKline	For profit	NDA	Nov 9, 1976
GlaxoSmithKline	For profit	MKTG	Dec 19, 1986